Cesca Therapeutics to Announce Second Quarter Fiscal 2016 Results and Provide a Status Update to Investors on February 16, 2016
11 févr. 2016 06h00 HE
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report...
Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)
02 févr. 2016 08h20 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will...
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
02 févr. 2016 08h16 HE
|
Adaptimmune Therapeutics plc
Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trialsCreates opportunity for up to eight combination studies LONDON, PHILADELPHIA...
Commence Bio Finalizes Corporate Identity Change From WibiWorks Therapeutics and Introduces New Website
04 janv. 2016 14h54 HE
|
Commence Bio
SPARKS, MD--(Marketwired - January 04, 2016) - Reflecting the STaRT™ of something big in immunotherapy, Commence Bio, Inc. today announced the completion of its corporate name change transition...
Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer
17 déc. 2015 11h30 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
Pluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications
12 oct. 2015 07h00 HE
|
Pluri Inc.
HAIFA, Israel, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced it has expanded...
Connecticut Children's Medical Center and Harvard Apparatus Regenerative Technology Collaborate to Develop Bioengineered Pediatric Esophageal Solutions
10 août 2015 10h46 HE
|
Connecticut Childrens Medical Center
HARTFORD, Conn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Connecticut Children's Medical Center has entered into an agreement with Harvard Apparatus Regenerative Technology, Inc., (NASDAQ: HART), or HART, a...
Endonovo Therapeutics Signs Funding Agreement for $10 Million
10 févr. 2014 09h00 HE
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA--(Marketwired - Feb 10, 2014) - Endonovo Therapeutics, Inc. (OTCQB: HVPA) ("Endonovo" or the "Company") announced that it has signed a best efforts funding agreement with an...
Hanover Portfolio Acquisitions Changes Its Name to Endonovo Therapeutics
28 janv. 2014 09h00 HE
|
Hanover Portfolio Acquisitions
LOS ANGELES, CA--(Marketwired - Jan 28, 2014) - Hanover Portfolio Acquisitions, (OTCQB: HVPA) has announced that it will now operate under the name Endonovo Therapeutics, effective immediately.
...
FDA Agreement on Mesoblast's Use of Singapore Manufacturing Facility for Clinical Trial Production of Proprietary Mesenchymal Precursor Cells
12 févr. 2013 20h28 HE
|
Mesoblast
MELBOURNE, Australia, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY) today announced that United States Food and Drug Administration (FDA) is in agreement for Mesoblast...